Stock Ratings / Health Care / DNTH / dividends

TVTX (52) PTCT (63) ERAS (33) EWTX (41) ⌘ Pro Terminal →

Dianthus Therapeutics Inc. (DNTH) Dividend Safety Gauge & 10-Year DRIP Compounder

$82.38 -0.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $82.17

Dianthus Therapeutics Inc. (DNTH) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $4.61B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DNTH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Dianthus Therapeutics Inc. (NASDAQ: DNTH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $82.38 (-0.39% 1D, market cap $4.61B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, DNTH ranks #478 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DNTH compare to TVTX and PTCT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DNTH carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.7%. By comparison, TVTX (Travere Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DNTH?

▼

Per DNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001690585), Dianthus Therapeutics Inc. generated $2.0M in revenue (-67.3% YoY), -$162.3M in net income, and -$129.2M in free cash flow against $530.9M in total assets and $16.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $82.17 (-0.26%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DNTH)Realized 20D OHLCV Swing Band: ±9.4%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY DNTH SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (28% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (46.8) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$74.76+4.5% Next Q

Q2 (-2Q)

Grade E$78.10+5.4% Next Q

Q3 (-1Q)

Grade E$82.31+0.1% Next Q

Current

Grade D-$82.38-7.6% Hist 90D α

Trajectory: E (31) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DNTH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DNTH currently carries a cautious 39/100 (D-) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($91.05) and Max Pain ($86.50) forces dealer call-delta covering toward $123.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DNTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DNTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DNTH)

✓Walkthrough of DNTH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DNTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.79%📐 HORIZONTAL RANGE

2026-11-03O $82.70H $82.70L $82.38C $82.38VOL 496.9K

RES: $137.4SUP: $65.05SMA50: $91.05SMA200: $85.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DNTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DNTH Butterfly Map → + Track DNTH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

13.5%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DNTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DNTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DNTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DNTH)

Health Care Rank #478 of 1016 ⚔️ TVTX vs DNTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DNTH vs. TVTX, PTCT, ERAS, EWTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dianthus Therapeutics Inc. (DNTH) ranks #478 by composite RQD confidence (39/100, grade D-) and #169 by equity capitalization ($4.61B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PTCT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with DNTH at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DNTH ACTIVE Dianthus Therapeutics Inc.	D-	39/100	—	—	-30.7%	-0.39%	$4.61B	Benchmark Subject
TVTX Travere Therapeutics Inc.	D+	52/100	—	96.0%	-13.0%	-0.36%	$4.75B	/tvtx-vs-dnth →
PTCT PTC Therapeutics Inc.	C	63/100	7.9x	—	85.0%	-6.97%	$5.01B	/ptct-vs-dnth →
ERAS Erasca Inc.	E	33/100	—	—	-35.0%	-4.21%	$5.02B	/eras-vs-dnth →
EWTX Edgewise Therapeutics Inc.	D-	41/100	—	—	-31.9%	-0.03%	$4.22B	/ewtx-vs-dnth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001690585

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dianthus Therapeutics Inc. (DNTH) reported GAAP revenue of $2.0M (-67.3% vs. FY2024 revenue of $6.2M , and -28.0% cumulative change since FY2023) , GAAP net income of -$162.3M, operating cash flow of -$129.1M, and free cash flow of -$129.2M (-64.6% YoY). On the balance sheet, DNTH closed FY2025 with $530.9M in total assets against $16.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.0M	-$162.3M	-$129.1M	-$129.2M	$530.9M	$16.9M
FY2024 (FY)	2024-12-31	$6.2M	-$85.0M	-$78.2M	-$78.5M	$374.0M	$9.7M
FY2023 (FY)	2023-12-31	$2.8M	-$43.5M	-$36.9M	-$37.0M	$2.54B	$595.3M

3. DNTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DNTH compare to TVTX and PTCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DNTH?

Where is DNTH trading relative to its 50-day, 200-day, and 52-week technical levels?

DNTH last traded at $82.38 (-0.39% on volume of 496,912 shares), positioning the stock -9.52% below its 50-day simple moving average ($91.05) and -3.76% below its 200-day simple moving average ($85.60). Across its 52-week range of $32.42 to $117.88, DNTH sits at the 58.5% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($74.64 to $90.12).

DNTH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does DNTH pay a dividend and is it safe?

Dianthus Therapeutics Inc. (DNTH) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: DNTH RQD Cockpit DNTH 12M Forecast DNTH Earnings & Move DNTH Dividends & DRIP DNTH Insiders & 13F DNTH Whale Options DNTH Profit Sankey DNTH News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DNTH — Dianthus Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:21:19Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DNTH scores 40 out of 100, graded D- under the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow."

Fundamental Cash Engine (9 / 20): Per the Roarable RQD rating, ROIC is -30.7% and FCF yield is -2.79%. The company is not currently generating returns on capital or positive free cash flow, so the cash engine is a weak pillar.
Whale 13F Flow (9 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The source does not provide 13F holder detail (see Analyst View section), so the score cannot be traced to specific holders.
Insider Conviction (6 / 20): Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. No insider transactions are listed in the source data.
Macro Regime Fit (5 / 20): Per the Roarable RQD rating, beta is 1.08 with sector sensitivity. This is the lowest pillar and indicates the stock's price behavior is expected to track broader market moves at slightly above-market volatility.
Forensic Balance Sheet (11 / 20): Per the Roarable RQD rating, Altman Z is 26, Piotroski F is 4/9, and Debt/Equity is 0.03. The leverage ratio is low, which supports the balance sheet relative to the other pillars, while the Piotroski score is middling.

Investor implications: the score reflects a company with heavy operating losses and negative cash flow, offset partly by a low-leverage balance sheet. An upside case rests on the market continuing to value the company despite losses; the valuation tradeoff is that forward P/E of 20 is shown alongside negative trailing EPS, so earnings expectations carry much of the valuation weight. The low macro-fit score suggests limited defensive characteristics. This is an analytical summary, not personalized advice.

Business

Per the profile section, Dianthus Therapeutics Inc. (DNTH) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The company's products, customers, and revenue model are not described in the source data. Per the SEC financials, reported revenue was $2.0M in FY 2025, $6.2M in FY 2024, and $2.8M in FY 2023. Market capitalization is $4.6B per the profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$2.0M	$-177.9M	$-162.3M	N/A	$-129.2M	$51.1M	$16.9M
FY 2024	$6.2M	$-101.9M	$-85.0M	N/A	$-78.5M	$22.8M	$9.7M
FY 2023	$2.8M	$-48.2M	$-43.5M	N/A	$-37.0M	N/A	$595.3M

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -30.7%. Per the Roarable RQD rating, Altman Z is 26, Piotroski F is 4/9, and Debt/Equity is 0.03. Reported operating losses and negative free cash flow widened across the three periods. Balance sheet posture per the RQD forensic pillar is low leverage, although the FY 2023 debt figure of $595.3M is substantially higher than the later periods and the source does not explain the change.

Recent Catalysts & News Wire Analysis

Per the recent news section, six items are listed, all tagged "MARKET WIRE" with YELLOW signal lights:

A Fortune 2026 Best Workplaces in BioPharma listing, reported via Yahoo Finance.
A MarketBeat consensus price target of $129.83, and a later MarketBeat average price target of $128.54.
A TradingView note that a Q3'26 revenue estimate of 460.93K USD exists.
A Stock Titan report of a Vanguard passive stake above 5%.
A Benzinga health care stock roundup mentioning DNTH.

Risk watch items: the revenue estimate of 460.93K USD sits well below FY 2025 reported revenue of $2.0M, which the source does not reconcile. The news items do not describe clinical, regulatory, or product catalysts. Per the Butterfly supply-chain graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's products, clinical programs, and revenue sources that generated the reported $2.0M in FY 2025 revenue?
What explains the drop in debt from $595.3M in FY 2023 to $16.9M in FY 2025, and how was the reduction funded?
Why is P/E (TTM) and EV/EBITDA unavailable, and what earnings trajectory underlies the forward P/E of 20?
How does the Q3'26 revenue estimate of 460.93K USD compare with the FY 2025 and FY 2024 revenue run-rates?
What is the cash runway given FY 2025 free cash flow of $-129.2M against $51.1M in cash?

DNTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dianthus Therapeutics Inc. (DNTH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DNTH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion

Yahoo Finance report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 19h ago

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Consensus Target Price of $129.83

MarketBeat report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 22h ago

DNTH Q3'26 Earnings: revenue estimate is 460.93K USD

TradingView report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Vanguard reports a passive stake above 5% in Dianthus Therapeutics (DNTH).

Stock Titan report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Benzinga report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Average Price Target of $128.54

MarketBeat report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Dianthus Therapeutics (DNTH) Slips 0.39% to $82.38, Holding Above $78.26 Support - Impulse Wave

https://www.dars.gov.et/ report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine India • 1d ago

Dianthus Therapeutics, Inc. (NASDAQ:DNTH): Latest Price, Valuation and Technical Overview

Kalkine India report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DNTH Bull vs. Bear Conversation Board — What's Your Call at $82.38?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DNTH 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $72.78 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DNTH (D- • RQD 40/100) a Buy at $82.70?

Welcome to the DNTH (Dianthus Therapeutics Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $62.03 (-25.0%)

Spot @ $82.70

Pump the brakes on DNTH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DNTH, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Dianthus Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $105.86 (+28.0%)

Spot @ $82.70

DNTH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DNTH, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $82.70 (52-wk range $32.28 - $117.88), any beat on forward guidance forces shorts and underweight funds to chase.